Delving into the Latest Updates on Pandemic H1N1 influenza vaccine(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms

Influenza A virus H1N1 vaccine intranasal, LAIV influenza A vaccine H1N1, Live-attenuated influenza virus vaccine H1N1

+ [2]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza A virus infectionInfluenza, Human

Inactive Indication-

Originator Organization

Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences

Active Organization

Serum Institute of India Pvt Ltd.

Inactive Organization

Changchun BCHT Biotechnology Co.

Drug Highest PhaseApproved

First Approval Date

IN (01 Jul 2010),

Influenza, Human

Regulation-

Login to view timeline

Author: Jagne, Ya Jankey ; Sallah, Hadijatou J ; Shaw, Helen A ; Marks, Michael ; Hornsby, Hailey ; Peno, Chikondi ; Armitage, Edwin P ; Senghore, Elina ; Bogaert, Debby ; Angyal, Adri ; Carducci, Martina ; Groves, Danielle ; Rossi, Omar ; Keeley, Alexander J ; de Silva, Thushan I ; Turner, Claire R ; de Crombrugghe, Gabrielle ; Kampmann, Beate ; Smeesters, Pierre R ; Drammeh, Sainabou

BACKGROUNDImmunity to Streptococcus pyogenes in high burden settings is poorly understood. We explored S. pyogenes nasopharyngeal colonization after intranasal live attenuated influenza vaccine (LAIV) among Gambian children aged 24-59 months, and resulting serological response to 7 antigens.METHODSA post hoc analysis was performed in 320 children randomized to receive LAIV at baseline (LAIV group) or not (control). S. pyogenes colonization was determined by quantitative polymerase chain reaction (qPCR) on nasopharyngeal swabs from baseline (day 0), day 7, and day 21. Anti-streptococcal IgG was quantified, including a subset with paired serum before/after S. pyogenes acquisition.RESULTSThe point prevalence of S. pyogenes colonization was 7%-13%. In children negative at day 0, S. pyogenes was detected at day 7 or 21 in 18% of LAIV group and 11% of control group participants (P = .12). The odds ratio (OR) for colonization over time was significantly increased in the LAIV group (day 21 vs day 0 OR, 3.18; P = .003) but not in the control group (OR, 0.86; P = .79). The highest IgG increases following asymptomatic colonization were seen for M1 and SpyCEP proteins.CONCLUSIONSAsymptomatic S. pyogenes colonization appears modestly increased by LAIV, and may be immunologically significant. LAIV could be used to study influenza-S. pyogenes interactions. Clinical Trials Registration. NCT02972957.

01 Jun 2023·Open forum infectious diseases

Epidemiological Impact of the Pediatric Live Attenuated Influenza Vaccine (LAIV) Program on Group A Streptococcus (GAS) Infection in England.

Article

Author: Guy, Rebecca ; Lamagni, Theresa ; Andrews, Nick ; Warburton, Fiona ; Watson, Conall ; Bernal, Jamie Lopez ; Sinnathamby, Mary A

BackgroundInfluenza is known to predispose to secondary bacterial infections including invasive group A streptococcal (iGAS) disease. The universal pediatric live attenuated influenza vaccine (LAIV) program introduced in England from the 2013/2014 influenza season was implemented incrementally, introducing cohorts of children annually to 2-16 years of coverage. Additionally, from the beginning of the program, discrete pilot areas offered LAIV vaccination to all primary school-age children, allowing for a unique comparison of infection rates between pilot and nonpilot areas during the program rollout.MethodsCumulative incidence rate ratios (IRRs) of GAS infections (all), scarlet fever (SF), and iGAS infection within each season by age group were compared for pilot and nonpilot areas using Poisson regression. The overall effect of the pilot program in the pre- (2010/2011-2012/2013 seasons) and postintroduction (2013/2014-2016/2017 seasons) periods was assessed using negative binomial regression by comparing changes in incidence between pilot/nonpilot areas (ratio of IRR [rIRR]).ResultsReductions in IRRs of GAS and SF were observed within most post-LAIV program seasons, among the age groups 2-4 and 5-10 years. Significant reductions were seen among 5-10 years (rIRR, 0.57; 95% CI, 0.45-0.71; P < .001), 2-4 years (rIRR, 0.62; 95% CI, 0.43-0.90; P = .011), and 11-16 years (rIRR, 0.63; 95% CI, 0.43-0.90; P = .018) for GAS infections when assessing the overall effect of the program.ConclusionsOur findings suggest that vaccination with LAIV may be associated with a reduced risk of GAS infection and support attaining high uptake of childhood influenza vaccination.

01 Feb 2023·Influenza and Other Respiratory Viruses

An intercountry comparison of the impact of the paediatric live attenuated influenza vaccine (LAIV) programme across the UK and the Republic of Ireland (ROI), 2010 to 2017

Article

Author: Pebody, Richard G. ; McMenamin, Jim ; Reynolds, Arlene J. ; Johnston, Jillian ; Yonova, Ivelina ; Elgohari, Suzanne ; Cottrell, Simon ; O'Doherty, Mark ; Sinnathamby, Mary A. ; Ellis, Joanna ; Warburton, Fiona ; O'Donnell, Joan ; Domegan, Lisa ; Andrews, Nick ; Boddington, Nicola L. ; de Lusignan, Simon

AbstractBackgroundThe universal paediatric live attenuated influenza vaccine (LAIV) programme commenced in the United Kingdom (UK) in 2013/2014. Since 2014/2015, all pre‐school and primary school children in Scotland and Northern Ireland have been offered the vaccine. England and Wales incrementally introduced the programme with additional school age cohorts being vaccinated each season. The Republic of Ireland (ROI) had no universal paediatric programme before 2017. We evaluated the potential population impact of vaccinating primary school‐aged children across the five countries up to the 2016/2017 influenza season.MethodsWe compared rates of primary care influenza‐like illness (ILI) consultations, confirmed influenza intensive care unit (ICU) admissions, and all‐cause excess mortality using standardised methods. To further quantify the impact, a scoring system was developed where each weekly rate/z‐score was scored and summed across each influenza season according to the weekly respective threshold experienced in each country.ResultsResults highlight ILI consultation rates in the four seasons' post‐programme, breached baseline thresholds once or not at all in Scotland and Northern Ireland; in three out of the four seasons in England and Wales; and in all four seasons in ROI. No differences were observed in the seasons' post‐programme introduction between countries in rates of ICU and excess mortality, although reductions in influenza‐related mortality were seen. The scoring system also reflected similar results overall.ConclusionsFindings of this study suggest that LAIV vaccination of primary school age children is associated with population‐level benefits, particularly in reducing infection incidence in primary care.

100 Deals associated with Pandemic H1N1 influenza vaccine(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences)

Login to view more data